Skye Bioscience Q3 net loss $3.9M; cash $76.5M; nimacimab Phase 2 enrolling, interim data Q2 2025

Skye Bioscience, Inc.

2024-Q3 EPS reported -$0.48

Net loss $3.9M in Q3 2024 vs $24.9M loss in Q3 2023; decrease driven by absence of $21.2M in-process R&D acquisition expense.
Cash and equivalents $76.5M including restricted $9.1M; court order allows release of $9M restriction before year-end.
Phase 2 obesity trial for nimacimab enrolling; interim data Q2 2025, topline data Q4 2025.
Preclinical DIO mouse model: nimacimab achieved up to 16% weight loss vs vehicle, with fat loss and lean mass preservation.
Appointed Dr. Puneet Arora as Chief Medical Officer and Paul Grayson as Chairman.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.